In a bold move to revolutionize at-home health monitoring, Withings has unveiled its latest gadget, the BeamO. Priced at R4,748.05, the BeamO is a 4-in-1 multiscope designed to measure temperature, conduct electrocardiograms (EKG), read blood oxygen levels, and function as a stethoscope to monitor heart and lung health.
The Withings BeamO integrates a range of cutting-edge technologies to offer a comprehensive health monitoring solution for families. Let’s take a closer look at its key features:
Similar to Withings’ Thermo thermometer, the BeamO allows users to take contactless temperature readings from the temporal artery, providing a quick and convenient way to monitor body temperature.
The device incorporates electrodes for EKG readings, enabling the detection of atrial fibrillation. With a piezoelectric disc, the BeamO captures acoustic noise from the chest or back, converting it into an electric signal for precise EKG measurements.
Equipped with photoplethysmography (PPG) sensors, the BeamO can measure blood oxygen levels, a crucial metric for assessing respiratory health. This feature is commonly found in smartwatches but is now condensed into a single device.
One of the most innovative aspects of the BeamO is its incorporation of a piezoelectric disc, allowing it to function as a stethoscope. By capturing acoustic noise from the chest or back, the device provides a novel way to monitor heart and lung health. The audio can be transferred to the Withings app or streamed directly to healthcare providers during telehealth sessions.
The BeamO aims to streamline the health monitoring process by consolidating multiple metrics into one device. Users can save their health data in PDFs for easy sharing with healthcare professionals. Additionally, the stethoscope’s audio can be seamlessly integrated into telehealth sessions, enhancing remote healthcare experiences.
While Withings anticipates the BeamO to be available for sale in June, potential challenges lie in the FDA clearance process. Features such as EKG and atrial fibrillation detection require regulatory approval, and delays in this process may impact the device’s release timeline. Withings has had past experiences with CES product announcements and subsequent FDA clearance delays, emphasizing the need for cautious optimism.
In conclusion, the Withings BeamO represents a significant leap in at-home health monitoring, offering a multifunctional device that caters to various health metrics. As the company continues to build its at-home health platform, South African consumers eagerly await the BeamO’s arrival, hopeful that it will bring a new era of accessible and efficient health monitoring to their homes.
This website uses cookies.
